Share Price and Basic Stock Data
Last Updated: October 14, 2025, 12:28 am
| PEG Ratio | 3.16 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Gujarat Inject (Kerala) Ltd operates in the pharmaceuticals sector and has reported a market capitalization of ₹30.2 Cr. The company’s stock price stood at ₹20.6. Over the past few quarters, the revenue trajectory has shown a significant upward shift. Sales for the quarter ending March 2024 reached ₹5.79 Cr, a notable increase from ₹0.17 Cr in March 2023. The trailing twelve months (TTM) revenue reported is ₹18.42 Cr, indicating a marked improvement compared to previous years. The sales growth appears to be on a positive trend with quarterly sales peaking at ₹8.61 Cr in September 2024, suggesting that the company is scaling its operations effectively. However, the recent quarters also exhibited fluctuating sales figures, with a drop to ₹0.00 Cr in September 2023, highlighting the potential volatility in revenue generation. The company’s ability to navigate these fluctuations will be critical for sustaining growth in a competitive industry.
Profitability and Efficiency Metrics
Gujarat Inject (Kerala) Ltd has demonstrated an evolving profitability profile, with a reported net profit of ₹1.02 Cr for the year ending March 2025, up from ₹0.04 Cr in March 2023. This growth in net profit translates into an earnings per share (EPS) of ₹0.70, a significant recovery from previous years where EPS was negative. The operating profit margin (OPM) for the latest fiscal year stood at 5.62%, reflecting improved operational efficiency compared to earlier margins which were negative. The company has also recorded a return on equity (ROE) of 10.15% and a return on capital employed (ROCE) of 12.54%, which are relatively solid figures in the pharmaceuticals sector. However, the cash conversion cycle (CCC) of 137.57 days raises concerns about the efficiency of working capital management, indicating that the company may take longer to convert its investments into cash flow, which could impact liquidity.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gujarat Inject (Kerala) Ltd reflects a cautious approach to leverage, with total borrowings reported at ₹0.00 Cr, indicating no reliance on debt financing. This absence of debt positions the company favorably in terms of financial stability. However, the reserves are negative at ₹-4.62 Cr, which could raise concerns regarding the retained earnings and overall equity base. The current ratio is reported at 4.73, suggesting a strong liquidity position that exceeds typical industry benchmarks, which often hover around 1.5-2.0 for healthy companies. The interest coverage ratio (ICR) stands at an impressive 837.07x, highlighting that the company can comfortably meet its interest obligations. The price-to-book value (P/BV) ratio is reported at 3.80x, which indicates that the stock may be priced above its book value, reflecting market confidence in its growth potential despite the negative reserves.
Shareholding Pattern and Investor Confidence
Investor confidence in Gujarat Inject (Kerala) Ltd appears robust, with public ownership standing at 100%. The number of shareholders has increased to 7,303 as of March 2025, up from 6,333 in September 2022, indicating growing interest and possibly positive sentiment towards the company’s future. The absence of promoter and institutional investor (FII/DII) participation might suggest that the company is still in a phase of establishing itself within the market. However, a fully public-held entity could also imply a broad-based support from retail investors. The shareholding structure indicates stability, but the lack of institutional backing may pose risks in terms of market perception and liquidity during downturns. Furthermore, the consistent public shareholding may signify a commitment to transparency and governance, which can enhance investor trust over time.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiencies improve, Gujarat Inject (Kerala) Ltd could capitalize on its growing revenue trajectory while maintaining a debt-free position. However, the company faces risks such as the potential volatility in sales and the negative reserves, which could impact its ability to reinvest in growth. Additionally, the high cash conversion cycle may strain liquidity if not managed effectively. The competitive landscape in the pharmaceuticals sector also poses challenges, requiring the company to innovate and adapt to market demands. If the company can leverage its strengths in financial stability and profitability while addressing these risks, it may establish a more robust market position and enhance shareholder value in the long run.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Gujarat Inject (Kerala) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 247/84.3 | 34.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,478 Cr. | 412 | 434/192 | 100 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 42.0 Cr. | 56.6 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.4 Cr. | 22.1 | 29.1/17.0 | 33.7 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,005.21 Cr | 1,173.36 | 50.09 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.04 | 0.03 | 0.10 | 0.00 | 0.15 | 0.00 | 0.22 | 5.42 | 3.05 | 8.61 | 3.15 | 4.24 | 2.42 |
| Expenses | 0.03 | 0.39 | 0.10 | 0.02 | 0.11 | 0.00 | 0.25 | 5.37 | 2.88 | 8.07 | 2.87 | 4.15 | 2.32 |
| Operating Profit | 0.01 | -0.36 | 0.00 | -0.02 | 0.04 | 0.00 | -0.03 | 0.05 | 0.17 | 0.54 | 0.28 | 0.09 | 0.10 |
| OPM % | 25.00% | -1,200.00% | 0.00% | 26.67% | -13.64% | 0.92% | 5.57% | 6.27% | 8.89% | 2.12% | 4.13% | ||
| Other Income | 0.00 | 0.40 | 0.00 | 0.03 | 0.00 | 0.02 | 0.04 | 0.00 | 0.00 | 0.17 | 0.00 | 0.01 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.04 | 0.00 | 0.01 | 0.04 | 0.02 | 0.01 | 0.05 | 0.17 | 0.71 | 0.28 | 0.10 | 0.10 |
| Tax % | 0.00% | 25.00% | 0.00% | 25.00% | 0.00% | 0.00% | 20.00% | 23.53% | 14.08% | 25.00% | 30.00% | 20.00% | |
| Net Profit | 0.01 | 0.03 | 0.00 | 0.01 | 0.03 | 0.01 | 0.00 | 0.04 | 0.12 | 0.61 | 0.21 | 0.07 | 0.07 |
| EPS in Rs | 0.02 | 0.06 | 0.00 | 0.02 | 0.06 | 0.02 | 0.00 | 0.04 | 0.08 | 0.42 | 0.14 | 0.05 | 0.05 |
Last Updated: August 19, 2025, 2:15 pm
Below is a detailed analysis of the quarterly data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2.42 Cr.. The value appears to be declining and may need further review. It has decreased from 4.24 Cr. (Mar 2025) to 2.42 Cr., marking a decrease of 1.82 Cr..
- For Expenses, as of Jun 2025, the value is 2.32 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.15 Cr. (Mar 2025) to 2.32 Cr., marking a decrease of 1.83 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.10 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For OPM %, as of Jun 2025, the value is 4.13%. The value appears strong and on an upward trend. It has increased from 2.12% (Mar 2025) to 4.13%, marking an increase of 2.01%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 20.00%, marking a decrease of 10.00%.
- For Net Profit, as of Jun 2025, the value is 0.07 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.07 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.05. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:00 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.02 | 1.57 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.17 | 5.79 | 19.05 | 18.42 |
| Expenses | 0.00 | 0.00 | 0.02 | 1.56 | 0.07 | 0.03 | 0.01 | 0.13 | 0.07 | 0.54 | 5.74 | 17.98 | 17.41 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.01 | -0.07 | -0.03 | -0.01 | -0.12 | -0.05 | -0.37 | 0.05 | 1.07 | 1.01 |
| OPM % | 0.00% | 0.64% | -1,200.00% | -250.00% | -217.65% | 0.86% | 5.62% | 5.48% | |||||
| Other Income | 0.00 | 0.00 | 2.30 | 0.00 | 0.05 | 0.02 | 0.01 | 0.01 | 0.05 | 0.43 | 0.06 | 0.18 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.06 | 0.11 | 1.25 | 1.19 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 18.18% | 19.20% | |||||
| Net Profit | 0.00 | 0.00 | 2.30 | 0.01 | -0.02 | -0.01 | 0.00 | -0.11 | 0.00 | 0.04 | 0.08 | 1.02 | 0.96 |
| EPS in Rs | 0.00 | 0.00 | 4.69 | 0.02 | -0.04 | -0.02 | 0.00 | -0.22 | 0.00 | 0.08 | 0.07 | 0.70 | 0.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2021-2022 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -99.57% | -300.00% | 50.00% | 100.00% | 100.00% | 100.00% | 1175.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -200.43% | 350.00% | 50.00% | 0.00% | 0.00% | 1075.00% |
Gujarat Inject (Kerala) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 884% |
| TTM: | 112% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 465% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 47% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 11% |
Last Updated: September 5, 2025, 3:40 pm
Balance Sheet
Last Updated: July 25, 2025, 1:10 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 4.88 | 11.29 | 14.63 |
| Reserves | -7.64 | -7.95 | -5.64 | -5.64 | -5.66 | -5.66 | -5.66 | -5.77 | -5.76 | -5.72 | -2.75 | -4.62 |
| Borrowings | 2.55 | 2.86 | 0.56 | 0.57 | 0.59 | 0.59 | 0.59 | 0.69 | 0.73 | 0.61 | 0.00 | 0.00 |
| Other Liabilities | 0.38 | 0.38 | 0.36 | 0.20 | 0.21 | 0.20 | 0.20 | 0.22 | 0.22 | 0.53 | 0.15 | 1.94 |
| Total Liabilities | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 |
| Fixed Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 |
| Total Assets | 0.17 | 0.17 | 0.16 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.07 | 0.30 | 8.69 | 11.95 |
Below is a detailed analysis of the balance sheet data for Gujarat Inject (Kerala) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.63 Cr.. The value appears strong and on an upward trend. It has increased from 11.29 Cr. (Mar 2024) to 14.63 Cr., marking an increase of 3.34 Cr..
- For Reserves, as of Mar 2025, the value is -4.62 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -2.75 Cr. (Mar 2024) to -4.62 Cr., marking a decline of 1.87 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1.94 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.15 Cr. (Mar 2024) to 1.94 Cr., marking an increase of 1.79 Cr..
- For Total Liabilities, as of Mar 2025, the value is 11.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.69 Cr. (Mar 2024) to 11.95 Cr., marking an increase of 3.26 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 11.95 Cr.. The value appears strong and on an upward trend. It has increased from 8.69 Cr. (Mar 2024) to 11.95 Cr., marking an increase of 3.26 Cr..
- For Total Assets, as of Mar 2025, the value is 11.95 Cr.. The value appears strong and on an upward trend. It has increased from 8.69 Cr. (Mar 2024) to 11.95 Cr., marking an increase of 3.26 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.62 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.55 | -2.86 | -0.56 | -0.56 | -0.66 | -0.62 | -0.60 | -0.81 | -0.78 | -0.98 | 0.05 | 1.07 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 137.57 | |||||
| Working Capital Days | -8,395.00 | -106.94 | -17,520.00 | -9,490.00 | -1,545.88 | 167.06 | 137.76 | |||||
| ROCE % | 2.65% | 13.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.70 | 0.09 | 0.05 | 0.00 | -0.12 |
| Diluted EPS (Rs.) | 0.70 | 0.09 | 0.05 | 0.00 | -0.12 |
| Cash EPS (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 6.84 | 7.57 | -1.71 | -1.80 | -1.80 |
| Revenue From Operations / Share (Rs.) | 13.01 | 5.13 | 0.35 | 0.04 | 0.02 |
| PBDIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBIT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| PBT / Share (Rs.) | 0.85 | 0.09 | 0.11 | 0.01 | -0.21 |
| Net Profit / Share (Rs.) | 0.69 | 0.07 | 0.08 | 0.00 | -0.21 |
| PBDIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBIT Margin (%) | 6.59 | 1.82 | 31.96 | 13.14 | -911.24 |
| PBT Margin (%) | 6.58 | 1.81 | 31.93 | 13.05 | -911.24 |
| Net Profit Margin (%) | 5.34 | 1.42 | 23.62 | 9.77 | -911.24 |
| Return on Networth / Equity (%) | 10.15 | 0.96 | -4.90 | -0.25 | 0.00 |
| Return on Capital Employeed (%) | 12.54 | 1.23 | -14.62 | -0.64 | 22.60 |
| Return On Assets (%) | 8.51 | 0.95 | 13.53 | 3.41 | -599.51 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -0.54 | -0.47 | -0.47 |
| Total Debt / Equity (X) | 0.00 | 0.00 | -0.72 | -0.83 | -0.78 |
| Asset Turnover Ratio (%) | 1.85 | 1.29 | 0.94 | 0.54 | 0.72 |
| Current Ratio (X) | 4.73 | 40.77 | 0.10 | 0.04 | 0.02 |
| Quick Ratio (X) | 4.73 | 40.77 | 0.10 | 0.04 | 0.02 |
| Interest Coverage Ratio (X) | 837.07 | 237.71 | 1108.59 | 144.19 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 679.13 | 187.11 | 820.29 | 108.27 | 0.00 |
| Enterprise Value (Cr.) | 36.07 | 8.32 | 4.38 | 1.48 | 0.00 |
| EV / Net Operating Revenue (X) | 1.89 | 1.44 | 25.18 | 65.66 | 0.00 |
| EV / EBITDA (X) | 28.73 | 78.68 | 78.78 | 499.58 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 2.00 | 1.94 | 22.04 | 33.50 | 0.00 |
| Price / BV (X) | 3.80 | 1.31 | -4.57 | -0.86 | 0.00 |
| Price / Net Operating Revenue (X) | 2.00 | 1.94 | 22.08 | 33.70 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Gujarat Inject (Kerala) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 0.70, marking an increase of 0.61.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 5. It has increased from 0.09 (Mar 24) to 0.70, marking an increase of 0.61.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 3. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.84. It has decreased from 7.57 (Mar 24) to 6.84, marking a decrease of 0.73.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 13.01. It has increased from 5.13 (Mar 24) to 13.01, marking an increase of 7.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.85. This value is within the healthy range. It has increased from 0.09 (Mar 24) to 0.85, marking an increase of 0.76.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 2. It has increased from 0.07 (Mar 24) to 0.69, marking an increase of 0.62.
- For PBDIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBIT Margin (%), as of Mar 25, the value is 6.59. This value is below the healthy minimum of 10. It has increased from 1.82 (Mar 24) to 6.59, marking an increase of 4.77.
- For PBT Margin (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 10. It has increased from 1.81 (Mar 24) to 6.58, marking an increase of 4.77.
- For Net Profit Margin (%), as of Mar 25, the value is 5.34. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 5.34, marking an increase of 3.92.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.15. This value is below the healthy minimum of 15. It has increased from 0.96 (Mar 24) to 10.15, marking an increase of 9.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 1.23 (Mar 24) to 12.54, marking an increase of 11.31.
- For Return On Assets (%), as of Mar 25, the value is 8.51. This value is within the healthy range. It has increased from 0.95 (Mar 24) to 8.51, marking an increase of 7.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.85. It has increased from 1.29 (Mar 24) to 1.85, marking an increase of 0.56.
- For Current Ratio (X), as of Mar 25, the value is 4.73. This value exceeds the healthy maximum of 3. It has decreased from 40.77 (Mar 24) to 4.73, marking a decrease of 36.04.
- For Quick Ratio (X), as of Mar 25, the value is 4.73. This value exceeds the healthy maximum of 2. It has decreased from 40.77 (Mar 24) to 4.73, marking a decrease of 36.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 837.07. This value is within the healthy range. It has increased from 237.71 (Mar 24) to 837.07, marking an increase of 599.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 679.13. This value is within the healthy range. It has increased from 187.11 (Mar 24) to 679.13, marking an increase of 492.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 36.07. It has increased from 8.32 (Mar 24) to 36.07, marking an increase of 27.75.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.44 (Mar 24) to 1.89, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 28.73. This value exceeds the healthy maximum of 15. It has decreased from 78.68 (Mar 24) to 28.73, marking a decrease of 49.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For Price / BV (X), as of Mar 25, the value is 3.80. This value exceeds the healthy maximum of 3. It has increased from 1.31 (Mar 24) to 3.80, marking an increase of 2.49.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has increased from 1.94 (Mar 24) to 2.00, marking an increase of 0.06.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gujarat Inject (Kerala) Ltd:
- Net Profit Margin: 5.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.54% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.15% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 679.13
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.73
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.7 (Industry average Stock P/E: 50.09)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.34%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Shop No. 15, K-Tower, Haveli Resi-Cum Plaza, Vadodra Gujarat 390014 | gikl2015@hotmail.com http://www.gujaratinject.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murli Nair | Whole Time Director |
| Ms. Reena Mahatma | Non Executive Director |
| Mr. Gautam Chauhan | Independent Director |
| Mr. Narayansinh Chauhan | Independent Director |
FAQ
What is the intrinsic value of Gujarat Inject (Kerala) Ltd?
Gujarat Inject (Kerala) Ltd's intrinsic value (as of 13 October 2025) is 20.66 which is 6.52% lower the current market price of 22.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹32.4 Cr. market cap, FY2025-2026 high/low of 29.1/17.0, reserves of ₹-4.62 Cr, and liabilities of 11.95 Cr.
What is the Market Cap of Gujarat Inject (Kerala) Ltd?
The Market Cap of Gujarat Inject (Kerala) Ltd is 32.4 Cr..
What is the current Stock Price of Gujarat Inject (Kerala) Ltd as on 13 October 2025?
The current stock price of Gujarat Inject (Kerala) Ltd as on 13 October 2025 is 22.1.
What is the High / Low of Gujarat Inject (Kerala) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gujarat Inject (Kerala) Ltd stocks is 29.1/17.0.
What is the Stock P/E of Gujarat Inject (Kerala) Ltd?
The Stock P/E of Gujarat Inject (Kerala) Ltd is 33.7.
What is the Book Value of Gujarat Inject (Kerala) Ltd?
The Book Value of Gujarat Inject (Kerala) Ltd is 6.83.
What is the Dividend Yield of Gujarat Inject (Kerala) Ltd?
The Dividend Yield of Gujarat Inject (Kerala) Ltd is 0.00 %.
What is the ROCE of Gujarat Inject (Kerala) Ltd?
The ROCE of Gujarat Inject (Kerala) Ltd is 13.5 %.
What is the ROE of Gujarat Inject (Kerala) Ltd?
The ROE of Gujarat Inject (Kerala) Ltd is 11.0 %.
What is the Face Value of Gujarat Inject (Kerala) Ltd?
The Face Value of Gujarat Inject (Kerala) Ltd is 10.0.